Literature DB >> 19165449

[Secondary malignant lymphedema in head and neck tumors].

Bernhard Hammerl1, Walter Döller.   

Abstract

The occurrence of edema is a serious problem of patients suffering from cancer and may have various causes. Particularly, the secondary malignant lymphedema poses a special threat to patients. In some cases, it indicates the progression of illness, and in fact also results in mutilating physical changes, which add to the already existing impairments caused by the cancer disease. So far therapeutic interventions are limited. Current management consists of physical therapy and pharmacological interventions. There are few powerful studies concerning the efficiency and hardly any concerning combined or comparative treatment in the literature. Most of them focus on the management of lymphedema in breast cancer patients. Preventive measures and supportive therapy are rarely being discussed. In this case report, we describe the successful use of Selen and Sandostatin in treating a facial edema of a patient with advanced head-neck cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19165449     DOI: 10.1007/s10354-008-0629-5

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  14 in total

1.  A universally applicable clinical classification of lymphedema.

Authors:  A J Miller; J Bruna; J Beninson
Journal:  Angiology       Date:  1999-03       Impact factor: 3.619

Review 2.  Lymphedema.

Authors:  S G Rockson
Journal:  Am J Med       Date:  2001-03       Impact factor: 4.965

Review 3.  Lymphedema: current issues in research and management.

Authors:  J A Petrek; P I Pressman; R A Smith
Journal:  CA Cancer J Clin       Date:  2000 Sep-Oct       Impact factor: 508.702

Review 4.  Prevention and management of arm lymphedema in the patient with breast cancer.

Authors:  Mehra Golshan; Barbara Smith
Journal:  J Support Oncol       Date:  2006-09

5.  Lymphedema: Knowledge, Treatment, and Impact Among Breast Cancer Survivors.

Authors:  Electra D. Paskett; Nancy Stark
Journal:  Breast J       Date:  2000-11       Impact factor: 2.431

Review 6.  Lymphedema: classification, diagnosis and therapy.

Authors:  A Szuba; S G Rockson
Journal:  Vasc Med       Date:  1998       Impact factor: 3.239

7.  Selenium in the treatment of radiation-associated secondary lymphedema.

Authors:  Oliver Micke; Frank Bruns; Ralph Mücke; Ulrich Schäfer; Michael Glatzel; Alexander F DeVries; Klaus Schönekaes; Klaus Kisters; Jens Büntzel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

8.  Somatostatin treatment of massive lymphorrhea following excision of a lymphatic malformation.

Authors:  Daniel W Suver; Jonathan A Perkins; Scott C Manning
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2004-06       Impact factor: 1.675

9.  Lack of effect of coumarin in women with lymphedema after treatment for breast cancer.

Authors:  C L Loprinzi; J W Kugler; J A Sloan; T W Rooke; S K Quella; P Novotny; R B Mowat; J C Michalak; P J Stella; R Levitt; L K Tschetter; H Windschitl
Journal:  N Engl J Med       Date:  1999-02-04       Impact factor: 91.245

10.  Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone.

Authors:  J R Casley-Smith; R G Morgan; N B Piller
Journal:  N Engl J Med       Date:  1993-10-14       Impact factor: 91.245

View more
  3 in total

1.  A Prospective Study of the Lymphedema and Fibrosis Continuum in Patients with Head and Neck Cancer.

Authors:  Sheila H Ridner; Mary S Dietrich; Kenneth Niermann; Anthony Cmelak; Kyle Mannion; Barbara Murphy
Journal:  Lymphat Res Biol       Date:  2016-06-15       Impact factor: 2.589

Review 2.  [Surgical therapy of secondary elephantoid lymphedema of the eyelids].

Authors:  A Sandner; A Lindner
Journal:  HNO       Date:  2015-01       Impact factor: 1.284

Review 3.  Lymphedema management in head and neck cancer.

Authors:  Brad G Smith; Jan S Lewin
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2010-06       Impact factor: 2.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.